insights_auto
Kāpēc uzņēmuma NVO akciju cena ir pieaugusi 2,42%?
Atklājiet vairāk iespējuchevron_right
NVO:NYSE
Novo Nordisk A/S
38,44 $
arrow_upward
+2,42%(+0,91) 1 d.
7. okt., 12:05:27 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: NVO…
Atvērt
37,57 $
Augsta
38,44 $
Zema
37,51 $
Tirgus kapitalizācija
128,05 mljrd.
Vid. apjoms
13,29 milj.
Apjoms
6,13 milj.
Dividende
4,67%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
9,75
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
3,94 $
Beta
0,75
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
37,57 $
Augsta
38,44 $
Zema
37,51 $
Tirgus kapitalizācija
128,05 mljrd.
Vid. apjoms
13,29 milj.
Apjoms
6,13 milj.
Dividende
4,67%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
9,75
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
3,94 $
Beta
0,75
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
AD HOC NEWS
·
pirms 19 minūtēm
Novo Nordisk stock gains 2.89 percent after-hours to EUR 34.18
Zacks
·
pirms 2 stundām
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Foreign Policy Journal
·
pirms 2 stundām
Novo Nordisk (NYSE: NVO) Stock Sits 70% Below Its Peak — Value Trap Or Generational Buying Opportunity?
Yahoo! Finance Canada
·
pirms 3 stundām
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Profils
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
Par “Novo Nordisk A/S”
ĢenerāldirektorsMaziar Mike Doustdar
Darbinieki66,7 tūkst.
Dibināšanas datums1923. gada 21. dec.
Galvenais birojsBagsværd, Galvaspilsētas reģions, Dānija
Sektors-
Tīmekļa vietnenovonordisk.com